HEPLISAV-B ® quarterly net product revenue of $79.3 million , representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24 $ 200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today at 4:30 p.m.
ET / 1:30 p.m. PT EMERYVILLE, Calif.
, Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX ), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended September 30, 2024 . "We are confident that the continued top-line growth of HEPLISAV-B sets the foundation for durable, long-term value creation.
We believe our commercial execution to date, overall financial position, and our commitment to achieving profitability, afford us the capacity to return cash to shareholders through the share repurchase program announced today. We will continue to execute on our strategic growth pillars focused on maximizing the HEPLISAV-B opportunity, delivering on our clinical pipeline, and pursuing external opportunities to drive sustainable value for our shareholders," said Ryan Spencer , Chief Executive Officer of Dynavax. "Addition.
